This website is intended for healthcare professionals practicing in Romania.
The Summary Product Characteristics of Dupilumab is available here.
Dupilumab is dispensed on medical prescription type PR.
For the request of medical information, the reporting of adverse reactions and / or quality complaints, please call the call center service 24/7, phone (+40) 021 317 31 36, or contact us by email at the following addresses: ro.medical_info@sanofi.com - Medical Department, quality.ro@sanofi.com - Quality Department, pv.ro@sanofi.com - Pharmacovigilance Department.
You may also report adverse reactions to Sanofi medicinal products to the National Agency for Medicines and Medical Devices from Romania (NAMMDR); for details on reporting side effects, visit the NAMMDR website.
© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.